While its a functional disorder without structural damage, BPC-157 may provide symptom relief by: Modulating nitric oxide and serotonin activity Reducing visceral pain and inflammation Normalizing motility through enteric nervous system regulation BPC-157s neural and anti-inflammatory support makes it a candidate for addressing both the gut-brain axis and local irritation in IBS patients
Product reviews (0) Features Evens out skin tone Suitable for all skin types Intensive hydration For a radiant glow Anti-wrinkle Ingredients Water, Dipropylene Glycol, Galactomyces Ferment Filtrate, Glycerin, Methylpropanediol, Glycereth-26, Niacinamide, Glyceryl Glucoside, Glyceryl Polymethacrylate, Erythritol, Polyglyceryl-10 Laurate, Hydroxyacetophenone, 1,2-Hexanediol, Carbomer, Caprylyl Glycol, Arginine, Hydrolyzed Jojoba Esters, Xanthan Gum, Adenosine, Glucose, Ethylhexylglycerin, Butylene Glycol, Citric Acid, Ascorbic Acid, Polyquaternium-51, Panthenol, Citrus Aurantium Bergamia Fruit Oil, Diethylhexyl Sodium Sulfosuccinate, Sodium Citrate, Lavandula Angustifolia Oil, Glutathione, Sodium Hyaluronate, Dipotassium Glycyrrhizate, Oryza Sativa Extract, Pyrus Malus Fruit Extract, Saccharide Isomerate, Hydrogenated Lecithin, Pantolactone, Maltodextrin, Brassica Oleracea Italica Extract, Hydrolyzed Vegetable Protein, Prunus Serrulata Flower Extract, Nelumbo Nucifera Germ Extract, Lilium Tigrinum Extract, Copper Tripeptide-1, Hydrolyzed Hyaluronic Acid, Hyaluronic Acid, Sodium Hyaluronate Crosspolymer, Hydroxypropyltrimonium Hyaluronate, Potassium Hyaluronate, Hydrolyzed Sodium Hyaluronate, Pentylene Glycol, Sodium Acetylated Hyaluronate, Disodium EDTA, Limonene, Linalool
However, further cross-species studies, long-term ecological monitoring, and in-depth mechanistic explorations are needed in the future to overcome the limitations of current studies
Bruin JE, Saber N, Braun N, et al
The occasional meat eater group exhibited a significantly greater reduction in TMAO levels after the fiber intervention compared to the regular meat-eating participants (mean difference [95% CI]: 1.96 [4.00, 0.083], p -value = 0.029)
Trial averages: 20.2% on tirzepatide and 13.7% on semaglutide at 72 weeks (SURMOUNT-5)
